EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial

YiXing Chen, Yong Hu, Jie Shen, ShiSuo Du, Jing Yan, LeYuan Zhou, Zhe Wang, HaiJie Lu, Lei Xiao, Ping Yang, WenChao Zhu, Jun Wang und 4 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025-02 · 121 (2) · 414-422

DOI: 10.1016/j.ijrobp.2024.09.021 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025-02. Verfasst von YiXing Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, Zhongshan Hospital Fudan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To compare the outcomes of transarterial chemoembolization (TACE) alone with those of TACE combined with external beam radiation therapy (EBRT) in patients with hepatocellular carcinoma (HCC) in a multicenter randomized study. METHODS AND MATERIALS: From 2017 to 2022, 74 HCC patients with tumors confined to the liver without vascular invasion were treated with either TACE only (TACE group, 39 patients) or TACE combined with EBRT (TACE + EBRT group, 35 patients). The primary outcome measured was overall survival (OS). Secondary outcomes included progression-free survival (PFS), local tumor control, and the assessment of treatment-related toxicity. RESULTS: Due to slow accrual, the trial was closed prematurely after enrolling 74 patients. All patients received 2 cycles of TACE before randomization. The TACE and TACE + EBRT groups showed comparable patient and tumor characteristics. The TACE group underwent a median of 3 TACE cycles, and the TACE + EBRT group received 2 cycles of TACE, and a median of 5500 cGy in 15 fractions. For the TACE group, the median local control (LC) duration was 13.1 months, whereas for the TACE + EBRT group, the median LC was not achieved (P < .001). The PFS was recorded at 11.6 months in the TACE group compared with 15.4 months in the TACE + EBRT group (P = .072). The median OS reached 36.8 months for the TACE group and extended to 47.1 months for the TACE + EBRT group (P = .654). The incidence of toxicity was comparable between both groups. CONCLUSIONS: Although the number of patients enrolled in this clinical trial did not meet expectations. TACE combined with EBRT was shown to be more effective than TACE alone in improving LC without increasing toxicity, whereas PFS and OS were slightly improved. TACE + EBRT can be used as a standard treatment option for patients with inoperable but confined intrahepatic HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticHumansFemaleMaleMiddle AgedAgedCombined Modality TherapyAdultProgression-Free SurvivalTreatment Outcome

Autor:innen und Institutionen

  • Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Comprehensive Cancer Centre, Department of Oncology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
  • Department of Radiation Oncology, the Fourth Affiliated Hospital of Soochow University, Suzhou, China.
  • Departement of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
  • Department of Radiation Oncology, Affiliated Zhongshan Hospital of Xiamen University, Xiamen, China.
  • Cancer Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.

Förderung

  • Ministry of Science and Technology of the People&apos;s Republic of China
  • Zhongshan Hospital Fudan University

Zitieren

APA

Chen, Y., Hu, Y., Shen, J., Du, S., Yan, J., Zhou, L., Wang, Z., Lu, H., Xiao, L., Yang, P., Zhu, W., Wang, J., Yang, G., Luo, J., Liu, R., & Zeng, Z. (2025). External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics, 121(2), 414-422. https://doi.org/10.1016/j.ijrobp.2024.09.021

Vancouver

Chen Y, Hu Y, Shen J, Du S, Yan J, Zhou L, et al. External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. 2025;121(2):414-422. doi:10.1016/j.ijrobp.2024.09.021

BibTeX
@article{Chen2025,
  author = {Chen, YiXing and Hu, Yong and Shen, Jie and Du, ShiSuo and Yan, Jing and Zhou, LeYuan and Wang, Zhe and Lu, HaiJie and Xiao, Lei and Yang, Ping and Zhu, WenChao and Wang, Jun and Yang, GuoWei and Luo, JianFeng and Liu, Rong and Zeng, ZhaoChong},
  title = {External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  volume = {121},
  number = {2},
  pages = {414--422},
  doi = {10.1016/j.ijrobp.2024.09.021}
}
Kostenlos starten →